Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 as consolidation for limited stage small-cell lung cancer
NCT07010263Phase 3Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jun 2025
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ivonescimab in small cell lung cancer (SCLC), sponsored by Akeso, Inc.. Started Jun 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07010263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07010263.